Zacks: Tocagen Inc (TOCA) Receives Average Rating of “Buy” from Analysts
Tocagen Inc (NASDAQ:TOCA) has earned an average broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and one has given a strong buy rating to the company.
Brokers have set a 12-month consensus price target of $23.67 for the company, according to Zacks. Zacks has also assigned Tocagen an industry rank of 110 out of 265 based on the ratings given to related companies.
A number of research analysts recently commented on TOCA shares. Stifel Nicolaus reaffirmed a “buy” rating and issued a $24.00 price target on shares of Tocagen in a report on Tuesday, July 25th. Zacks Investment Research downgraded shares of Tocagen from a “hold” rating to a “sell” rating in a report on Tuesday, August 15th. Finally, Leerink Swann started coverage on shares of Tocagen in a report on Monday, May 15th. They issued a “mkt perform” rating and a $19.00 price target for the company.
Several large investors have recently made changes to their positions in TOCA. TD Asset Management Inc. bought a new position in shares of Tocagen in the 2nd quarter valued at about $158,000. Schwab Charles Investment Management Inc. bought a new stake in Tocagen in the second quarter worth about $165,000. Alps Advisors Inc. bought a new stake in Tocagen in the second quarter worth about $215,000. Bank of New York Mellon Corp bought a new stake in Tocagen in the second quarter worth about $281,000. Finally, Victory Capital Management Inc. bought a new stake in Tocagen in the second quarter worth about $837,000. 37.87% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This report was posted by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/08/zacks-tocagen-inc-toca-receives-average-rating-of-buy-from-analysts.html.
Tocagen (NASDAQ TOCA) traded down 5.05% during midday trading on Friday, hitting $12.60. The stock had a trading volume of 81,668 shares. The company’s market capitalization is $249.59 million. Tocagen has a 1-year low of $9.68 and a 1-year high of $17.95. The stock’s 50-day moving average is $11.96 and its 200-day moving average is $13.46.
Tocagen (NASDAQ:TOCA) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.04. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million. Equities research analysts forecast that Tocagen will post ($2.51) EPS for the current year.
Tocagen Company Profile
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with MarketBeat.com's FREE daily email newsletter.